mk 767 has been researched along with rosiglitazone in 10 studies
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | mk 767 (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P | 1 |
| Berger, JP; Desai, RC; Doebber, TW; Franklin, R; Gratale, DF; Han, W; Heck, JV; Koyama, H; Leung, K; Lombardo, VK; MacNaul, KL; Metzger, E; Moller, DE; Sahoo, SP | 1 |
| Henke, BR | 1 |
| Endo, T; Kanda, T; Nakamura, H; Sakuma, S; Yamakawa, T; Yamasaki, S | 1 |
| Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M | 1 |
| Akanuma, Y; Ide, T; Kadowaki, T; Mochizuki, T; Murakami, K; Ohashi, M; Tobe, K; Yazaki, Y | 1 |
| Chaput, E; Edgar, AD; Saladin, R; Silvestre, M | 1 |
| Narce, M; Poisson, JP | 1 |
2 review(s) available for mk 767 and rosiglitazone
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
8 other study(ies) available for mk 767 and rosiglitazone
| Article | Year |
|---|---|
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors | 2003 |
Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.
Topics: Administration, Oral; Hypoglycemic Agents; Oxazoles; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors | 2003 |
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
Topics: Animals; Cell Differentiation; Cell Line; Cells, Cultured; Cerebral Cortex; Humans; Isoxazoles; Oligodendroglia; PPAR delta; Rats; Rats, Wistar | 2011 |
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain | 2012 |
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Hypoglycemic Agents; Insulin; Ligands; Lipid Metabolism; Liver; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Obesity; Organ Size; Oxidoreductases; Radioligand Assay; Rats; Rats, Wistar; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Transcriptional Activation; Triglycerides | 1998 |
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Topics: Acyl-CoA Oxidase; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Oxidoreductases; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors; Transcription Factors; Triglycerides | 2000 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |